These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30590833)

  • 1. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
    Emery P; Rondon J; Parrino J; Lin Y; Pena-Rossi C; van Hoogstraten H; Graham NMH; Liu N; Paccaly A; Wu R; Spindler A
    Rheumatology (Oxford); 2019 May; 58(5):849-858. PubMed ID: 30590833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
    Paccaly AJ; Kovalenko P; Parrino J; Boyapati A; Xu C; van Hoogstraten H; Ishii T; Davis JD; DiCioccio AT
    J Clin Pharmacol; 2021 Jan; 61(1):90-104. PubMed ID: 32726514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
    Genovese MC; van Adelsberg J; Fan C; Graham NMH; van Hoogstraten H; Parrino J; Mangan EK; Spindler A; Huizinga TWJ; van der Heijde D;
    Rheumatology (Oxford); 2018 Aug; 57(8):1423-1431. PubMed ID: 29746672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies.
    Ishii T; Sato Y; Munakata Y; Kajiwara M; Takahashi Y; van Hoogstraten H; Xu C; Kato N; Takahashi T
    Mod Rheumatol; 2023 Mar; 33(2):279-291. PubMed ID: 35445719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
    Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
    Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
    [No Abstract]   [Full Text] [Related]  

  • 6. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
    Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
    Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
    Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
    Fleischmann R; Genovese MC; Maslova K; Leher H; Praestgaard A; Burmester GR
    Rheumatology (Oxford); 2021 Nov; 60(11):4991-5001. PubMed ID: 33871596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
    Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
    J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis.
    Kovalenko P; Paccaly A; Boyapati A; Xu C; St John G; Nivens MC; Davis JD; Rippley R; DiCioccio AT
    CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):405-416. PubMed ID: 32453485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 Jun; 37(6):1471-1479. PubMed ID: 29404725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
    Fleischmann R; Genovese MC; Lin Y; St John G; van der Heijde D; Wang S; Gomez-Reino JJ; Maldonado-Cocco JA; Stanislav M; Kivitz AJ; Burmester GR
    Rheumatology (Oxford); 2020 Feb; 59(2):292-302. PubMed ID: 31312844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    Int J Clin Pharmacol Ther; 2021 Sep; 59(9):618-626. PubMed ID: 34281633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial.
    Emery P; van Hoogstraten H; Thangavelu K; Mangan E; St John G; Verschueren P
    ACR Open Rheumatol; 2020 Nov; 2(11):672-680. PubMed ID: 33164349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
    Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
    Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.
    Ma L; Xu C; Paccaly A; Kanamaluru V
    Clin Pharmacokinet; 2020 Nov; 59(11):1451-1466. PubMed ID: 32451909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.